A Study on the"Fuzheng"Therapy Promoted Immune Reconstitution to Improve the Survival of Early-stage Lung Cancer After Surgical Operation (CTC-TCM-FZ)

NCT02603003 Phase 1 COMPLETED

Metastasis is the leading cause of death in patients with lung cancer, and circulating tumor cells(CTCs) play a key role in the process of distant metastasis. The investigators' study will elaborate the clinical significance of CTCs intervented by Traditional Chinese Medicine(TCM) in lung cancer from the diagnosis and clinical staging,metastasis and recurrence, individual treatment and prognosis and so on, in order to provide a new direction for the treatment of lung cancer.

Details

Lead sponsor	Shanghai University of Traditional Chinese Medicine
Phase	Phase 1
Status	COMPLETED
Enrolment	218
Start date	2015-06
Completion	2019-09-01

Conditions

• Non-small Cell Lung Cancer(NSCLC)

Interventions

• JinFuKang
• Cisplatin
• Pemetrexed

Primary outcomes

• Progression-Free Survival — The progression disease is assessed based on CT or PET-CT every six months from date of randomization and the endpoints is the date of first documented progression or date of death due to lung cancer,assessed up to Two years.
  It is decided by a doctor via the clinical examinations